Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver

Patent metadata

Field	Value
Publication number	US-11331359-B2
Application number	US-201615208075-A
Country	US
Kind code	B2
Filing date	Jul 12, 2016
Priority date	Jul 15, 2015
Publication date	May 17, 2022
Grant date	May 17, 2022

Abstract

Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract, at least one Aloe gel powder, and at least one Schizandra extract. Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one Artemisia extract enriched for at least one polymer or biopolymer, at least one Aloe gel powder enriched for at least one chromone, and at least one Schizandra extract enriched for at least one lignan and organic acid.

First claim

We claim:

1. A composition for treatment of and maintaining the health of the liver, comprising a mixture of enriched plant extracts, wherein the enriched plant extracts comprise Artemisia capillaris extract enriched for at least one polymer or biopolymer, an Aloe gel powder enriched for at least one chromone, including aloesin, and Schizandra chinensis extract enriched for at least one lignan and organic acid, wherein the mixture of Artemisia capillaris, Schizandra chinensis and Aloe leaf gel powder is in a ratio of 8:4:3.

2. The composition of claim 1 , wherein the Artemisia extract comprises 0.01% to 99.9% of biopolymers with molecular weight higher than 500.

3. The composition of claim 1 , wherein the one or more biopolymers are extracted from Artemisia plant with water, methanol, ethanol, alcohol, a water-mixed solvent or a combination thereof.

4. The composition of claim 1 , wherein the Aloe gel powder comprises Aloe barbadensis.

5. The composition of claim 1 , wherein the at least one chromone composition comprises about 0.01% to about 100% of one or more chromones.

6. The composition of claim 1 , wherein the at least one lignan is isolated from a Schizandra extract is Schisandrin.

7. The composition of claim 1 , wherein the at least one organic acid is isolated from a Schizandra extract includes malic acid.

8. The composition of claim 1 , wherein the plant extracts are derived from at least one plant part selected from the group consisting of stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves, other aerial parts or a combination thereof.

9. The composition of claim 1 , wherein the composition additionally comprises at least one liver protectant.

10. The composition of claim 9 , wherein the liver protectant comprises plant powder or plant extract of milk thistle.

11. The composition of claim 9 , wherein the liver protectant comprises plant powder or plant extract of milk thistle, curcuma, bupleurum , licorice, salvia, morus, hovenia , agrimony, cudrania , lyceum, citrus, prunus , yellow mume, Korea gim, dandelion, vitis , grape seed, rubus, camellia , green tea, krill oil, yeast, soy bean; isolated and enriched silymarins, flavonoids, phospholipids, thios, pycnogenols, gelatins, soy lecithin, pancreatic enzymes; natural or synthetic N-acetyl-cysteine, taurine, riboflavin, niacin, pyridoxine, folic acid, carotenes, vitamin A, vitamin B2, B6, B16, vitamin C, vitamin E, glutathione, branched-chain amino acids, selenium, copper, zinc, manganese, coenzyme Q10, L-arginine, L-glutamine, phosphatidylcholine or a combination thereof.

12. The composition of claim 1 , wherein the composition further comprises a pharmaceutically or nutraceutically acceptable carrier, diluent, or excipient.

13. The composition of claim 1 , wherein the composition comprises from about 0.5 weight percent (wt %) to about 90 wt % of active ingredients of the mixture of plant extracts.

14. The composition of claim 13 , wherein the composition is formulated as a tablet, hard capsule, soft gel capsule, powder, granule, liquid, tincture, sachet, ready to drink shot, or lozenge.

15. The composition of claim 1 , wherein the composition is administered at a dose of 0.01 to 500 mg/kg of body weight of the animal.

16. A medical composition for maintaining liver function, minimizing liver cell damage, promoting healthy liver, neutralizing toxins, diminishing the action of free radicals on the liver, scavenging reactive oxygen species, reducing oxidative stress, preventing the formation of toxic metabolisms, improving liver detoxification capacity and/or function, liver cleansing, restoring liver structure, protecting liver cells from toxins, helping liver's blood flow and circulation, supporting liver function, alleviating liver pain, purging toxic chemicals and organisms, supporting liver's metabolic process, alleviating liver discomfort, alleviating fatty liver, improving liver detoxification capacity, lowering liver enzymes, increasing SOD, increasing GSH, reducing liver cell peroxidation, reducing fatty acid accumulation, improving liver immune function, promoting liver cell regeneration, improving liver renewal function, stimulating bile release, promoting healthy bile flow, liver rejuvenating, wherein the medical composition contains the composition of claim 1 as an effective ingredient.

17. The medical composition of claim 16 , wherein the liver disorder or disease is viral hepatitis, alcohol hepatitis, autoimmune hepatitis, alcohol liver disease, fatty liver disease, steatosis, steatohepatitis, non-alcohol fatty liver disease, drug-induced liver disease, cirrhosis, fibrosis, liver failure, drug induced liver failure, metabolic syndrome, hepatocellular carcinoma, cholangiocarcinoma, primary biliary cirrhosis, bile capillaries, Gilbert's syndrome, jaundice, or any combination thereof.

Assignees

• Unigen Inc

Inventors

• Jia Qi
• Yimam Mesfin
• Jiao Ping
• Hong Mei Feng
• Moore Breanna

Classifications

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K2236/333

  using mixed solvents, e.g. 70% EtOH · CPC title

• A61K36/886

  Aloeaceae (Aloe family), e.g. aloe vera · CPC title

• A61K2236/51

  Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying · CPC title